The global surge in diabetes cases is a key factor propelling the artificial pancreas device market, as a larger patient base fuels the need for effective diabetes management tools. Growing awareness and widespread screening initiatives have also contributed to earlier diagnoses and improved disease control, reinforcing the demand for advanced technologies such as artificial pancreas systems. Furthermore, ongoing product innovation and development by leading companies have led to more efficient and accessible devices, boosting market growth.
New York, USA, June 18, 2025 (GLOBE NEWSWIRE) — Global Artificial Pancreas Devices Market is Gearing Up for Outstanding Expansion at a CAGR of ~16% by 2032 | DelveInsight
The global surge in diabetes cases is a key factor propelling the artificial pancreas device market, as a larger patient base fuels the need for effective diabetes management tools. Growing awareness and widespread screening initiatives have also contributed to earlier diagnoses and improved disease control, reinforcing the demand for advanced technologies such as artificial pancreas systems. Furthermore, ongoing product innovation and development by leading companies have led to more efficient and accessible devices, boosting market growth.
DelveInsight’s Artificial Pancreas Devices Market Insights report provides the current and forecast market analysis, individual leading artificial pancreas devices companies’ market shares, challenges, artificial pancreas devices market drivers, barriers, trends, and key market artificial pancreas devices companies in the market.
Key Takeaways from the Artificial Pancreas Devices Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global artificial pancreas devices market during the forecast period.
- In the device type segment of the artificial pancreas device market, the threshold-suspended device system had the highest revenue share in the year 2024.
- Notable artificial pancreas devices companies such as Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., BIGFOOT BIOMEDICAL, INC., CamDiab Ltd., Diabeloop SA, Ypsomed, INREDA® DIABETIC B.V., Nikkiso Co., Ltd., Pancreum, Inc., Johnson & Johnson Services, Inc., Dexcom, Inc., TypeZero Technologies, Animas Corporation, and several others are currently operating in the artificial pancreas device market.
- In September 2024, Tandem Diabetes Care, Inc., announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology was cleared for use with Eli Lilly and Company’s Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU).
- In June 2024, MCRA, a leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm, announced its role in assisting CamDiab’s artificial pancreas software, CamAPS FX, in achieving U.S. Food and Drug Administration (FDA) clearance.
To read more about the latest highlights related to the artificial pancreas devices market, get a snapshot of the key highlights entailed in the Global Artificial Pancreas Devices Market Report
Artificial Pancreas Devices Overview
Artificial pancreas devices represent a significant technological advancement in the management of type 1 diabetes, offering an automated solution to maintain optimal blood glucose levels. These systems typically combine a continuous glucose monitor (CGM), an insulin pump, and a sophisticated control algorithm that calculates and delivers insulin doses in real time. By mimicking some functions of a healthy pancreas, these devices help reduce the burden of frequent glucose monitoring and insulin administration, improving glycemic control and reducing the risk of both hyperglycemia and hypoglycemia.
Recent innovations have led to the development of hybrid closed-loop systems, which require minimal patient intervention and can automatically adjust insulin delivery based on sensor readings. These devices have shown promising results in clinical trials and real-world settings, enhancing quality of life and long-term health outcomes for people with diabetes. Ongoing research is focused on improving algorithm accuracy, integrating dual hormone (insulin and glucagon) systems, and enhancing interoperability with smartphones and wearable technologies to create fully autonomous and user-friendly artificial pancreas solutions.
Artificial Pancreas Devices Market Insights
North America is projected to dominate the artificial pancreas device market in the coming years. This leadership can be attributed to several factors, including the growing prevalence of diabetes, increased government healthcare initiatives, the presence of major industry players engaged in strategic product innovations, and greater public awareness about diabetes management. Notably, rising awareness plays a significant role in driving demand for advanced diabetes care technologies such as artificial pancreas systems. For example, collaborative efforts by the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) through programs like the National Diabetes Education Program (NDEP) aim to educate communities about continuous glucose monitoring and automated insulin delivery systems.
Moreover, active product development and regulatory approvals continue to strengthen the market. A key milestone includes the FDA approval in May 2024 of the CamAPS FX artificial pancreas, developed by the University of Cambridge, for use in individuals with type 1 diabetes aged two years and above, including pregnant women.
Collectively, these factors are expected to significantly fuel the growth of the artificial pancreas device market in North America throughout the 2025–2032 forecast period.
To know more about why North America is leading the market growth in the artificial pancreas devices market, get a snapshot of the Artificial Pancreas Devices Market Outlook
Artificial Pancreas Devices Market Dynamics
The artificial pancreas devices market is witnessing strong growth driven by increasing global prevalence of type 1 diabetes and advancements in diabetes management technologies. As patient demand for convenient and accurate diabetes management tools rises, healthcare providers and manufacturers are increasingly focusing on developing integrated, closed-loop systems that mimic the glucose-regulating function of a healthy pancreas.
Technological innovation is a core driver of the market, with developments in real-time glucose monitoring, machine learning algorithms, and smartphone integration enhancing the usability and precision of artificial pancreas systems. Companies are also leveraging cloud connectivity to enable remote patient monitoring and data sharing with healthcare providers. These advancements are improving both patient outcomes and physician decision-making while reducing the burden of disease management. The adoption of hybrid closed-loop systems, which allow partial automation, has paved the way for fully automated solutions, many of which are currently in advanced stages of clinical trials or have already gained regulatory approvals in key markets like the U.S. and Europe.
Regulatory support and favorable reimbursement policies in several countries are also propelling market growth. Additionally, public and private payers are beginning to cover these systems, recognizing their long-term benefits in reducing diabetes-related complications and hospitalizations. However, in developing countries, market penetration remains limited due to high device costs and insufficient healthcare infrastructure.
Despite these promising trends, the market faces notable challenges. High upfront costs of artificial pancreas systems, coupled with the need for regular maintenance and consumables, can deter widespread adoption, especially in low- and middle-income regions. Technical limitations, such as sensor calibration requirements, occasional device malfunction, and user training complexity, can also hinder patient acceptance and adherence. Furthermore, data security and privacy concerns regarding cloud-connected health devices must be carefully managed to maintain trust among users and healthcare providers.
Looking ahead, the artificial pancreas market is poised for robust growth, supported by continuous innovation, strategic partnerships, and rising consumer awareness. Industry players are investing in R&D to enhance the accuracy, affordability, and user-friendliness of these systems. As the ecosystem evolves, integration with digital health platforms and expansion into emerging markets are expected to open new avenues for growth, ultimately moving closer to the vision of a fully automated, reliable, and accessible solution for diabetes management.
Get a sneak peek at the artificial pancreas devices market dynamics @ Artificial Pancreas Devices Market Trends
| Report Metrics | Details |
| Coverage | Global |
| Study Period | 2022–2032 |
| Artificial Pancreas Devices Market CAGR | ~16% |
| Artificial Pancreas Devices Market Size by 2032 | USD 1.1 Billion |
| Key Artificial Pancreas Devices Companies | Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., BIGFOOT BIOMEDICAL, INC., CamDiab Ltd., Diabeloop SA, Ypsomed, INREDA® DIABETIC B.V., Nikkiso Co., Ltd., Pancreum, Inc., Johnson & Johnson Services, Inc., Dexcom, Inc., TypeZero Technologies, Animas Corporation, among others |
Artificial Pancreas Devices Market Assessment
- Artificial Pancreas Devices Market Segmentation
- Artificial Pancreas Devices Market Segmentation By Device Type: Threshold Suspended Device System and Non-Threshold Suspended Device System
- Artificial Pancreas Devices Market Segmentation By End User: Hospitals & Clinics, Homecare Settings, Ambulatory Surgical Centers, and Others
- Artificial Pancreas Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the artificial pancreas devices market are set to emerge as the trendsetter explore @ Artificial Pancreas Devices Companies
Table of Contents
| 1 | Artificial Pancreas Devices Market Report Introduction |
| 2 | Artificial Pancreas Devices Market Executive Summary |
| 3 | Competitive Landscape |
| 4 | Regulatory Analysis |
| 5 | Artificial Pancreas Devices Market Key Factors Analysis |
| 6 | Artificial Pancreas Devices Market Porter’s Five Forces Analysis |
| 7 | Artificial Pancreas Devices Market Layout |
| 8 | Artificial Pancreas Devices Market Company and Product Profiles |
| 9 | KOL Views |
| 10 | Project Approach |
| 11 | About DelveInsight |
| 12 | Disclaimer & Contact Us |
Interested in knowing the artificial pancreas devices market by 2032? Click to get a snapshot of the Artificial Pancreas Devices Market Analysis
Related Reports
Diabetes Market
Diabetes Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others.
Diabetes Pipeline
Diabetes Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetes companies, including Daewoong Pharmaceutical, Janssen Biotech, Zealand Pharma, BioRestorative Therapies, Elevian, Oramed Pharmaceuticals, ImCyse, Novo Nordisk, Enthera, Precigen, Inc., Japan Tobacco, Avotres, AstraZeneca, Landos Biopharma, Vertex Pharmaceuticals, REMD Biotherapeutics, Inc., Eledon Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, Diamyd Medical, NextCell Pharma, ViaCyte, Op-T LLC, Dompé Farmaceutici S.p.A, ILTOO Pharma, Throne Biotechnologies, Oramed Pharmaceuticals, Janssen Research & Development, LLC, Jaguar Gene Therapy, SQZ Biotechnologies, Genprex, Inc., CRISPR Therapeutics, Biora Therapeutics, Genprex, Inc., among others.
Type 1 Diabetes Market
Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others.
Type 2 Diabetes Market
Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., among others.
Type 2 Diabetes Pipeline
Type 2 Diabetes Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679
- Premier Dallas Criminal Defense Appeals Attorney John Helms Provides Comprehensive Guide to Criminal Appeals Process - June 18, 2025
- Avis Budget Group, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 24, 2025 Deadline to file Lead Plaintiff Motion - June 18, 2025
- Open Lending Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. June 30, 2025 Deadline to file Lead Plaintiff Motion. - June 18, 2025
